c-Met: A potential therapeutic target for hepatocellular carcinoma-Reference-Cited by-同舟云学术

c-Met: A potential therapeutic target for hepatocellular carcinoma

Published:2011 Issue:1 Volume:5 Page:2-11
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Gao Jianjun¹²,Inagaki Yoshinori²,Xue Xia¹,Qu Xianjun¹,Tang Wei¹²

Affiliation:

1. School of Pharmaceutical Sciences, Shandong University

2. Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Reference88 articles.

1. 1. International Agency for Research on Cancer. Cancer Incidence and Mortality Worldwide in 2008 (GLOBOCAN 2008). http://globocan.iarc.fr (accessed November 21, 2010).

2. 2. American Cancer Society. Cancer Facts and FIGS 2005. http://www.cancer.org/docroot/home/index.asp (accessed November 21, 2010).

3. 3. Song PP, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong JH, Kokudo N. The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation. Biosci Trends. 2010; 4:283-287.

4. 4. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100:698-711.

5. 5. Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010; 42 (Suppl 3):S302-S309.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between the HGF/c‑MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review);Oncology Reports;2021-07-13

2. Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose;CPT: Pharmacometrics & Systems Pharmacology;2021-05

3. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors;Clinical Cancer Research;2019-12-10

4. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma;World Journal of Gastroenterology;2019-08-07

5. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway;Artificial Cells, Nanomedicine, and Biotechnology;2019-01-19